Neovascular Glaucoma

  • Donald Minckler


Neovascular glaucoma (NVG) is an apt generic term originally proposed by Weiss and colleagues in 1963 for the secondary glaucoma due to proliferation of fibrovascular tissue with progressive closure of the anterior chamber angle.1,2 Simply defined, neovascularization (NV) in any organ system implies growth of vessels into or onto tissues not normally vascularized, such as cornea, vitreous, sub-retinal space, and the iris and meshwork surfaces and interstices.


Vascular Endothelial Growth Factor Central Retinal Vein Occlusion Corneal Edema Retinal Ischemia Neovascular Glaucoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Weiss DI, Shaffer RN, Nehrenberg TR. Neovascular glaucoma complicating carotid-cavernous fistula. Arch Ophthalmol. 1963;69:304–307.PubMedGoogle Scholar
  2. 2.
    Wand M. Neovascular glaucoma. In: Ritch R, Shields MB, Krupin T, eds. The Glaucomas - Clinical Science. 2nd ed. St. Louis: Mosby; 1996:1073-1129. Ch 51.Google Scholar
  3. 3.
    Sivak-Callcott JA, O’Day DM, Gass JD, et al. Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology. 2001;108:1767–1776.CrossRefPubMedGoogle Scholar
  4. 4.
    Hayreh SS. Neovascular glaucoma. Prog Retin Eye Res. 2007;26(5):470–485.CrossRefPubMedGoogle Scholar
  5. 5.
    Yoneya S, Numaga T, Yamazaki S, et al. Neovascularization of iris demonstrated in kittens with ROP. Nippon Ganka Gakkai Zasshi. 1982;86(9):1251–1261.PubMedGoogle Scholar
  6. 6.
    Bron AJ, Tripathi RC, Tripathi BJ. Wolff’s Anatomy of the Eye and Orbit. London: Chapman and Hall Medical; 1993:377. Ch 11.Google Scholar
  7. 7.
    Sassani JT, Eagle RC. The myofibroblastic component of rubeosis iridis. Ophthalmology. 1983;90:721–728.PubMedGoogle Scholar
  8. 8.
    Diabetes control and complications trial research group. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology. 1995;102:647–661.Google Scholar
  9. 9.
    Ohnishi Y, et al. Fluorescein gonioangiography in diabetic neovascularization. Graefes Arch Clin Exp Ophthalmol. 1994;232:199–204.CrossRefPubMedGoogle Scholar
  10. 10.
    Diabetic retinopathy study group. Preliminary report on effects of photocoagulation therapy. Am J Ophthalmol.. 1976;81:383–396.Google Scholar
  11. 11.
    Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25:581–611.CrossRefPubMedGoogle Scholar
  12. 12.
    Andreoli CM, Miller JW. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol. 2007;18:502–508.CrossRefPubMedGoogle Scholar
  13. 13.
    Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina. 2006;26:354–356.CrossRefGoogle Scholar
  14. 14.
    Davidorf FH, Mouser JG, Derick RJ. Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. Retina. 2006;26:354–356.CrossRefPubMedGoogle Scholar
  15. 15.
    Kahook MY, Schuman JS, Noecker RJ. Intravitreal bevacizumab in a patient with neovascular glaucoma. Ophthalmic Surg Lasers Imaging. 2006;37:144–146.PubMedGoogle Scholar
  16. 16.
    Paula JS, Jorge R, Costa RA, et al. Short-term results of intravitreal bevacizumab (Avastin) on anterior segment neovascularization in neovascular glaucoma. Acta Ophthalmol Scand. 2006;84:556–557.CrossRefGoogle Scholar
  17. 17.
    Grisanti S, Bieter S, Peters S, et al. The Tuebingen bevacizumab study group. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol. 2006;142:158–160.CrossRefPubMedGoogle Scholar
  18. 18.
    Yazdani S, Hendi K, Pakravan M. Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma. J Glaucoma. 2007;16:437–439.CrossRefPubMedGoogle Scholar
  19. 19.
    Bakri SJ, Snyder R, Reid JM, et al. Pharamoacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. 2007;114:2179–2182.CrossRefPubMedGoogle Scholar
  20. 20.
    Katz LJ, Costa VP, Spaeth GL. Filtration surgery. In: Ritch R, Shields MB, Krupin T, eds. The Glaucomas. 2nd ed. St. Louis: Mosby; 1996:1682. Ch 83.Google Scholar
  21. 21.
    Tsai JC, Feuer WJ, Parrish RK 2nd, et al. 5-Flurouracil filtering surgery and neovascular glaucoma - long-term follow-up of the original pilot study. Ophthalmology. 1995;102:887–892.PubMedGoogle Scholar
  22. 22.
    Kitazawa Y, Kawase K, Matsushita H, et al. Trabeculectomy with mitomycin. A comparative study with fluorouracil. Arch Ophthalmol. 1991;109:1693–1698.PubMedGoogle Scholar
  23. 23.
    Sisto D, Vetrugno M, Trabucco T, et al. The role of anti­metabolites in filtration surgery for neovascular glaucoma: intermediate-term follow-up. Acta Ophthalmol Scand. 2007;85:267–271.CrossRefPubMedGoogle Scholar
  24. 24.
    Sidoti PA, Morinelli EN, Heuer DK, et al. Tissue plasminogen activator and glaucoma drainage implants. J Glaucoma. 1995;4:258–262.PubMedGoogle Scholar
  25. 25.
    Every SG, Molteno AC, Bevin TH, et al. Long-term results of Molteno implant insertion in cases of neovascular glaucoma. Arch Ophthalmol. 2006;124:355–360.CrossRefPubMedGoogle Scholar
  26. 26.
    Broadway DC, Tester M, Schulzer M, et al. Survival analysis for success of Molteno tube implants. Br J Ophthalmol. 2001;85:689–695.CrossRefPubMedGoogle Scholar
  27. 27.
    Susanna R Jr, Latin American Glaucoma Society. Partial Tenon’s capsule resection with adjunctive MMC in Ahmed glaucoma valve implant surgery. Br J Ophthalmol. 2003;87:994–998.CrossRefPubMedGoogle Scholar
  28. 28.
    Costa VP, Azuara-Blanco A, Netland PA, et al. Efficacy and safety of adjunctive mitomycin-C during Ahmed glaucoma valve implantation: a prospective randomized clinical trial. Ophthalmology. 2004;111:1071–1076.CrossRefPubMedGoogle Scholar
  29. 29.
    Cantor L, Burgoyne J, Sanders S, et al. The effect of mitomycin C on Molteno implant surgery: a 1-year randomized masked, prospective study. J Glaucoma. 1998;7:240–246.CrossRefPubMedGoogle Scholar
  30. 30.
    Duan X, Jiang Y, Qing G. Long-term follow-up study on Hunan aqueous drainage implantation combined with mitomycin-C for refractory glaucoma. Yan Ke Xue Bao Bian Ji Bu. 2003;19(2):81–85.Google Scholar
  31. 31.
    Lima FE, Magacho L, Carvalho DM, et al. A prospective, comparative study between endoscopic cyclophotocoagulation and the Ahmed drainage implant in refractory glaucoma. J Glaucoma. 2004;13:233–237.CrossRefPubMedGoogle Scholar
  32. 32.
    Callens C, D’Hondt K, Zeyen T. The long-term effect of diode laser cyclodestruction on intraocular pressure. Bull Soc Belge Ophthalmol. 2003;289:81–86.Google Scholar
  33. 33.
    Hamard P, Gayraud JM, Kopel J, et al. Treatment of refractory glaucomas by transscleral cyclophotocoagulation using semiconductor diode laser. Analysis of 50 patients followed-up over 19 months. J Fr Ophthalmol. 1997;20:125–133.Google Scholar
  34. 34.
    Kahook MY, Lathrop KL, Noecker RJ. One-site versus two-site cyclophotocoagulation. J Glaucoma. 2007;16:527–530.CrossRefPubMedGoogle Scholar
  35. 35.
    Duke-Elder S, Jay B. System of ophthalmology. Haemorrhagic Glaucoma, vol. XI. London: Henry Kimpton; 1969:667.Google Scholar


  1. Cursiefen, C., M. Kuchle, et al. 2001. Pseudoexfoliation syndromein eye with ischemic central retinal vein occlusion: a histopathologic and electron microscopic study. Acta Ophthalmol Scand. 79: 476–478.CrossRefPubMedGoogle Scholar
  2. Hayreh, S.S. 1998. Central retinal vein occlusion. Ophthalmol Clin North Am. 11: 559–590.CrossRefGoogle Scholar
  3. Hayreh SS, et al. Hemi-central retinal vein occlusion. Pathogenesis, clinical features and natural history. Arch Opthalmol. 1980;98:1600–1609.Google Scholar
  4. Hayreh, S.S., et al. 2004. IOP abnormalities associated with central and hemicentral retinal vein occlusion. Ophthalmology. 111(1): 133–141.CrossRefPubMedGoogle Scholar
  5. Hayreh, S.S., et al. 2001. Systemic diseases associates with various type of retinal vein occlusion. Am J Ophthalmol. 131: 61–77.CrossRefPubMedGoogle Scholar
  6. Moore, R.F. 1922. Some observation on intraocular tension in cases of thrombosis of retinal veins. Trans Ophthalmol Soc UK 42: 115–126.Google Scholar
  7. Saatci, O.A., S.T. Ferliel, et al. 1999. Pseudoexfoliation and glaucoma in eyes with retinal vein occlusion. Int Ophthalmol. 23: 75–78.CrossRefPubMedGoogle Scholar
  8. Verhoeff, F.H. 1913. The effect of chronic glaucoma on the central retinal vessels. Arch Opthalmol. 42: 145–152.Google Scholar


  1. Aiello, L.P., R.L. Avery, P.G. Arrigg, et al. 1994. VEGF in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 331: 1519–1520.CrossRefGoogle Scholar
  2. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report. Ophthalmology. 1995;102:1434–1444.Google Scholar
  3. Boyd, S.R., I. Zachary, U. Chakravarthy, et al. 2002. Correlation of increased VEGF with NV and permeability in ischemic central vein occlusion. Arch Ophthalmol. 120: 1644–1650.PubMedGoogle Scholar
  4. Ferrara, D.C., H. Koizumi, and R.F. Spaide. 2007. Early bevacizumab treatment of central retinal vein occlusion. Am J Ophthalmol. 144: 864–871.CrossRefPubMedGoogle Scholar
  5. Hayreh, S.S. 2007. Neovascular Glaucoma. Prog Retin Eye Res. 26(5): 470–485.CrossRefPubMedGoogle Scholar
  6. Hayreh SS, Rojas P, Podhajsky P, et al. Ocular NV with retinal vascular occlusion - III. Incidence of ocular NV with retinal vein occlusion. Ophthalmology. 1983;90:488–506.PubMedGoogle Scholar
  7. Hsu, J., R.S. Kaiser, A. Sivalingam, et al. 2007. Intravitreal bevacizumab (Avastin) in central retinal vein occlusion. Retina. 27: 1013–1019.CrossRefPubMedGoogle Scholar
  8. Pe’er J, Folberg R, Itin A, et al. VEGF upregulation in human central retinal vein occlusion. Ophthalmology. 1998;105:412–416.CrossRefPubMedGoogle Scholar
  9. Priluck, I.A., D.M. Robertson, and R.W. Hollenhorst. 1980. Long-term follow-up of occlusion of the central retinal vein in young adults. Am J Ophthalmol. 90: 190–202.PubMedGoogle Scholar
  10. Prilinger, S.G., A.H. Wolf, T.C. Kreutzer, et al. 2007. Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: 6-month results of a prospective trial. Retina. 27: 1004–1012.CrossRefGoogle Scholar
  11. Rubeosis Anti-VEGF (RAVE) Trial for Ischemic Central Retinal Vein Occlusion. Accessed August 30, 2008.
  12. The Central Vein Occlusion Study Group. 1993. Baseline and early natural history report. Arch Ophthalmol 111: 1087–1095.Google Scholar
  13. The Central Vein Occlusion Study Group. 1997. Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol. 115: 486–491.Google Scholar
  14. Tripathi, R.C., J. Li, B.J. Tripathi, et al. 1998. Increased level of VEGF in aqueous humor of patients with NVG. Ophthalmology. 105: 232–237.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Donald Minckler
    • 1
  1. 1.Department of Ophthalmology & PathologyUniversity of CaliforniaIrvineUSA

Personalised recommendations